Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer-Reference-Cited by-同舟云学术

Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer

Published:2018-08-27 Issue:10 Volume:128 Page:4413-4428
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Mabe Nathaniel W.,Fox Douglas B.,Lupo Ryan,Decker Amy E.,Phelps Stephanie N.,Thompson J. Will,Alvarez James V.

Funder

National Cancer Institute

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/99481/files/pdf

Reference62 articles.

1. Breast Cancer Statistics at a Glance. Surveillance, Epidemiology, and End Results (SEER) Program. National Cancer Institute. https://seer.cancer.gov/statfacts/html/breast.html Accessed August 21, 2018

2. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

3. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer

4. EMT, CTCs and CSCs in tumor relapse and drug-resistance;Mitra;Oncotarget,2015

5. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Tumor Suppressor Par-4 Regulates Adipogenesis by Transcriptional Repression of PPARγ;Cells;2024-09-05

2. Targeting tumor-associated macrophages with nanocarrier-based treatment for breast cancer: A step toward developing innovative anti-cancer therapeutics;Heliyon;2024-09

3. Pharmacological targeting of the cancer epigenome;Nature Cancer;2024-06-27

4. Anticancer genes (NOXA, PAR-4, TRAIL) are de-regulated in breast cancer patients and can be targeted by using a ribosomal inactivating plant protein (riproximin);Molecular Biology Reports;2023-05-01

5. Anticancer genes (NOXA, PAR-4, TRAIL) are de-regulated in breast cancer patients and can be targeted by using a ribosomal inactivating plant protein (riproximin);2023-01-18